Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11075200 | 0.91 | MEN1 (0.46) | MEN1KMT2ATSHRNPSR1ALOX5 | |
| SCHEMBL11461531 | 0.87 | ALOX5 (0.44) | MEN1KMT2ATSHRNPSR1ALOX5 | |
| SCHEMBL13662524 | 0.84 | POLB (0.45) | SMN1; SMN2L3MBTL1TSHRNPSR1ALOX5 | |
| SCHEMBL11068628 | 0.84 | MEN1 (0.51) | MEN1KMT2ATSHRNPSR1ALOX5 | |
| SCHEMBL27928436 | 0.84 | MEN1 (0.51) | MEN1KMT2ATSHRNPSR1ALOX5 | |
| SCHEMBL2806112 | 0.80 | HTT (0.50) | SMN1; SMN2ALOX5KDM4EHTTRIPK1 | |
| SCHEMBL1642904 | 0.80 | HTT (0.50) | SMN1; SMN2ALOX5KDM4EHTTRIPK1 | |
| Ammonia Solution, Strong SCHEMBL23877941 | 0.78 | HTT (0.49) | SMN1; SMN2ALOX5KDM4EHTTRIPK1 | |
| SCHEMBL8632615 | 0.77 | POLB (0.47) | MEN1KMT2ASMN1; SMN2TSHRNPSR1 | |
| SCHEMBL11118605 | 0.77 | ALOX5 (0.49) | MEN1KMT2ATSHRNPSR1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589219-B2 | 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2009-09-15 | — | — | US | disclosed |
| US-7589219-B2 | 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2009-09-15 | — | — | US | disclosed |
| US-7589219-B2 | 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2009-09-15 | — | — | US | disclosed |
| US-20050261345-A1 | 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2005-11-24 | — | — | US | disclosed |
| EP-1497257-A1 | 2,5-BIS-DIAMINE-[1,4] BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE, A PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREFOR | Alma Mater Studiorum -Universita' di Bologna (IT) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087035-A1 | 2,5-BIS-DIAMINE-'1,4! BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE A PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREFOR | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261345-A1 | 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor | PSEN2, BACE2, WEE2 | MEN1 1177/4885KMT2A 1451/4885SMN1; SMN2 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.